M. van Glabbeke

45.9k citations

198 papers · 36.0k indexed · 13 hit papers · h-index 65

Impact in

Gastroenterology top 0.02%
- Gastrointestinal Tumor Research and Treatment
Otorhinolaryngology top 0.02%
- Head and Neck Cancer Studies

Papers in

Gastroenterology 30
- Gastrointestinal Tumor Research and Treatment 30
Otorhinolaryngology 17
- Head and Neck Cancer Studies 17

Co-authors: Jaap Verweij Allan T. van Oosterom J. Wanders Elizabeth A. Eisenhauer Patrick Therasse Susan G. Arbuck Michaele C. Christian Richard Kaplan
Journals: European Journal of Cancer (52 papers)Journal of Clinical Oncology (33 papers)Annals of Oncology (12 papers)Radiotherapy and Oncology (12 papers)International Journal of Radiation Oncology*Biology*Physics (9 papers)
Partner nations: Belgium Netherlands France

In The Last Decade

M. van Glabbeke

197 papers receiving 35.1k citations

Hit Papers

13 papers align trajectories log scale

Lymphopenia as a Prognostic Factor for Overall Survival in Advanced Carcinomas, Sarcomas, and Lymphomas 2009 · 624 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2009 Cancer Research
2009 Journal of Clinical Oncology
2006 European Journal of Cancer
2005 Annals of Oncology
2005 Head & Neck
2004 New England Journal of Medicine
2004 The Lancet
2001 The Lancet
2000 JNCI Journal of the National Cancer Institute
1997 Journal of Clinical Oncology
1996 International Journal of Radiation Oncology*Biology*Physics
1992 Radiotherapy and Oncology
1979 European Journal of Cancer (1965)

Peers

Countries citing papers authored by M. van Glabbeke

Since Specialization

Citations

This map shows the geographic impact of M. van Glabbeke's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M. van Glabbeke with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M. van Glabbeke more than expected).

Fields of papers citing papers by M. van Glabbeke

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M. van Glabbeke. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M. van Glabbeke. The network helps show where M. van Glabbeke may publish in the future.

Co-authors

The 25 scholars most cited alongside M. van Glabbeke, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with M. van Glabbeke Line = papers co-authored together M. van Glabbeke links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	BCL-2/IgH Polymerase Chain Reaction Status at the End of Induction Treatment Is Not Predictive for Progression-Free Survival in Relapsed/Resistant Follicular Lymphoma: Results of a Prospective Randomized EORTC 20981 Phase III Intergroup Study Journal of Clinical Oncology ·Marinus H. J. van Oers, Evelyn Tönnissen, M. van Glabbeke, L. Giurgea, Joop H. Jansen, Richard Klasa, Robert Marcus, Max Wolf, Eva Kimby, Andrej Vranovský, Harald Holte, Anton Hagenbeek, Bert A. van der Reijden	2010	34
2	DOG1 and CD117 are the antibodies of choice in the diagnosis of gastrointestinal stromal tumours Histopathology ·Marco Novelli, Sabrina Rossi, Manuel Rodriguez‐Justo, Philippe Tanière, Beatrice Seddon, Luisa Toffolatti, Chiara Sartor, Pancras C.W. Hogendoorn, Raf Sciot, M. van Glabbeke, Jaap Verweij, Jean‐Yves Blay, Peter Hohenberger, Adrienne M. Flanagan, Angelo Paolo Dei Tos	2010	129
3	Pazopanib, a Multikinase Angiogenesis Inhibitor, in Patients With Relapsed or Refractory Advanced Soft Tissue Sarcoma: A Phase II Study From the European Organisation for Research and Treatment of Cancer–Soft Tissue and Bone Sarcoma Group (EORTC Study 62043) Journal of Clinical Oncology ·Stefan Sleijfer, Isabelle Ray‐Coquard, Zsuzsa Pápai, Axel Le Cesne, Michelle Scurr, Patrick Schöffski, Françoise Collin, Lini Pandite, Sandrine Marréaud, Annick De Brauwer, M. van Glabbeke, Jaap Verweij, Jean‐Yves Blay Hit paper breakdown →	2009	535
4	Improvement in Histologic Response But Not Survival in Osteosarcoma Patients Treated With Intensified Chemotherapy: A Randomized Phase III Trial of the European Osteosarcoma Intergroup JNCI Journal of the National Cancer Institute ·Ian Lewis, M. Nooij, Jeremy Whelan, Matthew R. Sydes, R. J. Grimer, Pancras C.W. Hogendoorn, Muhammad Ali Memon, Simon Weeden, Barbara Uscinska, M. van Glabbeke, Anne Kirkpatrick, Esther Hauben, Alan Craft, Antonïe H.M. Taminiau	2007	272
5	Scientific review of EORTC trials European Journal of Cancer ·C Lardot, W P Steward, M. van Glabbeke, Jean‐Pierre Armand	2002	6
6	Chimeric anti-CD20 monoclonal antibody (Mabthera) in remission induction and maintenance treatment of relapsed follicular non-Hodgkin's lymphoma: a phase III randomized clinical trial - Intergroup Collaborative Study Annals of Hematology ·Marinus van Oers, Anton Hagenbeek, M. van Glabbeke, Ivana Teodorović	2002	20
7	The achievements of the EORTC Lymphoma Group European Journal of Cancer ·John Raemaekers, Hanneke C. Kluin‐Nelemans, Ivana Teodorović, C Meerwaldt, E.M. Noordijk, José Thomas, M. van Glabbeke, M. Henry‐Amar, Patrice Carde	2002	49
8	A retrospective analysis of the results of p(65) + Be neutrontherapy for the treatment of prostate adenocarcinoma at the cyclotron of Louvain-la-Neuve. Part I: survival and progression-free survival Cancer/Radiothérapie ·Pierre Scalliet, Vincent Remouchamps, F. Lhoas, M. van Glabbeke, Desmond Curran, Tatiana Ledent, André Wambersie, F. Richard, Paul Van Cangh	2001	6
9	A randomised phase II study on neo-adjuvant chemotherapy for ‘high-risk’ adult soft-tissue sarcoma European Journal of Cancer ·E. Gortzak, Alberto Azzarelli, J. Buesa, V. Bramwell, Frits van Coevorden, A.N. van Geel, Adnan Ezzat, Armando Santoro, J. Wolter Oosterhuis, M. van Glabbeke, A. Kirkpatrick, Jaap Verweij	2001	275
10	Randomized Phase II Study of Docetaxel versus Doxorubicin in first- and second-line chemotherapy for locally advanced or metastatic soft tissue sarcomas in adults: A Study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. International Journal of Clinical Oncology ·Jaap Verweij, S.M. Lee, W. Ruka, J. Buesa, Robert L. Coleman, Q.G.C.M. van Hoesel, C. Seynaeve, Eugenio Donato Di Paola, M. van Glabbeke, D. Tonelli, Ian Judson	2000	30
11	A phase II study of cisplatin, ifosfamide and doxorubicin in operable primary, axial skeletal and metastatic osteosarcoma Annals of Oncology ·P.A. Voûte, R L Souhami, M. Nooij, R. Somers, H. Cortés-Funes, Jan W. van der Eijken, J. Pringle, Pancras C.W. Hogendoorn, A. Kirkpatrick, Barbara Uscinska, M. van Glabbeke, David Machin, Simon Weeden	1999	38
12	Phase II trial of vinorelbine in metastatic squamous cell esophageal carcinoma. European Organization for Research and Treatment of Cancer Gastrointestinal Treat Cancer Cooperative Group. Journal of Clinical Oncology ·Thierry Conroy, Pierre-Luc Etienne, Antoine Adenis, D J Wagener, B Paillot, Éric François, Laurent Bedenne, J H Jacob, Jean‐François Seitz, Harry Bleiberg, C van Pottelsberghe, M. van Glabbeke, F.M. Delgado, S Merle, J. Wils	1996	68
13	Paclitaxel for malignant pleural mesothelioma: a phase II study of the EORTC Lung Cancer Cooperative Group British Journal of Cancer ·Jan P. van Meerbeeck, C. Debruyne, Nico van Zandwijk, PE Postmus, MC Pennucci, Frank van Breukelen, Danny Galdermans, Harry J.M. Groen, P. Pinson, M. van Glabbeke, Eric Van Marck, Giuseppe Giaccone	1996	67
14	[Design, management and handling of a randomized trial]. PubMed ·Aleksey V. Ivanov, M. van Glabbeke	1995	2
15	Efficacy of four different regimens in 64 mantle-cell lymphoma cases Journal of Clinical Oncology ·Ivana Teodorović, Stefania Pittaluga, Hanneke C. Kluin‐Nelemans, J.H. Meerwaldt, Anton Hagenbeek, M. van Glabbeke, R. Somers, Luc Bijnens, E.M. Noordijk, C Peeters	1995	4
16	The predictive value of cell kinetic measurements in a European trial of accelerated fractionation in advanced head and neck tumors: An interim report International Journal of Radiation OncologyBiologyPhysics ·A.C. Begg, Ingrid Hofland, L. Moonen, Harry Bartelink, S Schraub, P. Bontemps, R. Le Fur, W. Van den Bogaert, Robert J.L. Caspers, M. van Glabbeke, Jean-Claude Horiot	1990	158
17	Phase II trial of idarubicin (4-demethoxydaunorubicin) in advanced breast cancer European Journal of Cancer and Clinical Oncology ·P Hurteloup, P. Armand, Martina Schneider, P Bastit, B Chevallier, C Pourny, R Keiling, Carlos Augusto Fernandes de Oliveira, M. Hayat, D. Thomas, M. van Glabbeke, Paul Rebattu, G Mathé	1989	12
18	Phase II trial of Menogaril in advanced malignant melanoma. An EORTC trial European Journal of Cancer and Clinical Oncology ·S. Gundersen, S. Monfardini, G Renard, M. van Glabbeke, Herbert M. Pinedo	1987	2
19	Prognostic factors in non-Hodgkin's lymphoma International Journal of Radiation OncologyBiologyPhysics ·M Tubiana, Patrice Carde, J. M. V. Burgers, Jean‐Marc Cosset, M. van Glabbeke, R. Somers	1986	19
20	Split course multiple daily fractionated radiotherapy schedule combined with misonidazole for the management of grade III and IV gliomas A pilot feasibility study of the Radiotherapy Group of the EORTC International Journal of Radiation OncologyBiologyPhysics ·K. Kian Ang, Emmanuel van der Schueren, Gustave Notter, Jean Claude Horiot, Christian Chenal, F. Fauchon, Jules Raps, Henny van Peperzeel, Jean Claude Goffin, Michel Vessière, M. van Glabbeke	1982	35

About M. van Glabbeke

M. van Glabbeke is a scholar working on Gastroenterology, Otorhinolaryngology, Pulmonary and Respiratory Medicine, Oncology and Pathology and Forensic Medicine, having authored 198 papers that have together received 36.0k indexed citations. Recurring topics across this work include Sarcoma Diagnosis and Treatment (67 papers), Lymphoma Diagnosis and Treatment (43 papers), Vascular Tumors and Angiosarcomas (35 papers), Gastrointestinal Tumor Research and Treatment (30 papers), Cancer Treatment and Pharmacology (19 papers), Head and Neck Cancer Studies (17 papers), Viral-associated cancers and disorders (17 papers) and Gastric Cancer Management and Outcomes (16 papers). The work is most often cited by research in Gastroenterology (5.3k citations), Otorhinolaryngology (4.1k citations), Oncology (15.5k citations), Pulmonary and Respiratory Medicine (18.4k citations) and Hepatology (2.0k citations). M. van Glabbeke has collaborated with scholars based in Belgium, Netherlands and France. Frequent co-authors include Jaap Verweij, Allan T. van Oosterom, J. Wanders, Elizabeth A. Eisenhauer, Patrick Therasse, Susan G. Arbuck, Michaele C. Christian, Richard Kaplan, Larry Rubinstein and Ian Judson. Their work appears in journals such as European Journal of Cancer, Journal of Clinical Oncology, Annals of Oncology, Radiotherapy and Oncology and International Journal of Radiation Oncology*Biology*Physics.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact